Clinical Trials Logo

Condylomata Acuminata clinical trials

View clinical trials related to Condylomata Acuminata.

Filter by:

NCT ID: NCT05518201 Completed - Anal Cancer Clinical Trials

Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old

Start date: September 23, 2022
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of the 9vHPV vaccine in Chinese healthy male aged 9 to 45 years.

NCT ID: NCT05372016 Completed - Cervical Cancer Clinical Trials

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Start date: September 19, 2020
Phase: Phase 3
Study type: Interventional

The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.

NCT ID: NCT05371353 Recruiting - Vaginal Cancer Clinical Trials

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Start date: May 14, 2022
Phase:
Study type: Observational

To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.

NCT ID: NCT05314023 Active, not recruiting - Genital Warts Clinical Trials

Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)

Start date: May 7, 2022
Phase: Phase 3
Study type: Interventional

This study is designed to demonstrate non-inferior immunogenicity of 3 doses of the 9-Valent Human Papillomavirus (9vHPV) vaccine (GARDASIL™9, V503) in Chinese males 9 through 19 years of age, and 2 doses of the 9vHPV vaccine in Chinese males 9 through 14 years of age, compared to the 3 dose regimen in Chinese males 20 through 26 years of age (from Merck Protocol V503-052). The primary hypothesis is that each of the 3-dose regimen in Chinese males aged 9 through 19 years and 2-dose regimens in Chinese males aged 9 through 14 years induces non-inferior competitive Luminex immunoassay (cLIA) geometric mean titers (GMTs) at one month post last dose compared to the 3-dose regimen in Chinese adult males aged 20 through 26 years. A noninferiority margin of 0.67 in the GMT ratio (9 through 19 years of age or 9 through 14 years of age vs 20 through 26 years of age) is used for each HPV type.

NCT ID: NCT05156541 Completed - Clinical trials for Human Papillomavirus Infection

Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts

ING-HPV-1
Start date: May 18, 2009
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to evaluate the effectiveness of destructive therapy for anogenital warts in combination with the use of Ingaron in comparison with destructive therapy.

NCT ID: NCT05100043 Completed - Warts Hand Clinical Trials

Interleukin 4 and Interferon Gamma Predictors of Human Papillomavirus Immunotherapy in Warts

Start date: January 3, 2020
Phase:
Study type: Observational

In the present study the investigators assessed the invitro role of IL-4 and IFN-γ in predicting the response to bivalent HPV vaccine after whole blood stimulation

NCT ID: NCT05087849 Recruiting - Clinical trials for Human Papilloma Virus

Intralesional HPV Vaccine for Condylomata

Start date: April 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will investigate whether injecting genital warts with small quantities of the Gardasil 9 vaccine has an effect on the warts.

NCT ID: NCT05056402 Active, not recruiting - Cervical Cancer Clinical Trials

An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old

Start date: September 19, 2021
Phase: Phase 3
Study type: Interventional

This is a open label clinical trial to evaluate the safety and immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., in healthy population aged 9-17 years old in comparison with aged 18-26.

NCT ID: NCT05027776 Recruiting - Vaginal Cancer Clinical Trials

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Start date: September 15, 2021
Phase: Phase 3
Study type: Interventional

This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years

NCT ID: NCT04905030 Enrolling by invitation - Cervical Cancer Clinical Trials

Education, Immigration and HPV Vaccination: an Informational Randomized Trial

Start date: April 28, 2021
Phase: N/A
Study type: Interventional

Counteracting misinformation on childhood vaccines remains a priority for public health in industrialized countries. Previous research showed that misinformation-induced vaccine hesitancy particularly concerns very highly or very lowly educated parents, and, especially in Europe, specific groups of immigrants. Misinformation framing directly targets specific sub-population of parents by exploiting different cognitive biases, and specific concerns based on cultural norms: this project aims at testing the effectiveness of similar framing techniques applied to positive information on the HPV vaccine by conducting a Randomized Controlled Trial in Stockholm, Sweden. It randomizes emotionally and scientifically/statistically framed information addressing the specific concerns reported by previous literature.